Commentary: Somatostatin analogs-How we choose, and why

Semin Oncol. 2017 Apr;44(2):157-158. doi: 10.1053/j.seminoncol.2017.08.001. Epub 2017 Aug 4.

Authors

Diane Reidy-Lagunes¹, Nitya Raj², Leonard Saltz²

Affiliations

¹ Gastrointestinal Oncology Service, Department of Medicine, Memorial Department of Medicine, Weill Cornell Medical College, New York, NY. Electronic address: reidyd@mskcc.org.
² Gastrointestinal Oncology Service, Department of Medicine, Memorial Department of Medicine, Weill Cornell Medical College, New York, NY.

PMID: 28923214
DOI: 10.1053/j.seminoncol.2017.08.001

No abstract available

MeSH terms

Antineoplastic Agents, Hormonal / economics
Antineoplastic Agents, Hormonal / pharmacology*
Antineoplastic Agents, Hormonal / therapeutic use
Decision Making
Humans
Neuroendocrine Tumors / drug therapy*
Octreotide / pharmacology
Octreotide / therapeutic use
Peptides, Cyclic / economics
Peptides, Cyclic / pharmacology*
Peptides, Cyclic / therapeutic use
Practice Guidelines as Topic
Somatostatin / analogs & derivatives*
Somatostatin / economics
Somatostatin / pharmacology
Somatostatin / therapeutic use

Substances

Antineoplastic Agents, Hormonal
Peptides, Cyclic
lanreotide
Somatostatin
Octreotide